{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:26Z","timestamp":1792511546089,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi261095-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Although cisplatin-based neoadjuvant chemotherapy for patients with localized muscle-invasive blader cancer (MIBC) is associated with improved survival, nearly half of these patients are ineligible for cisplatin-based chemotherapy and historically proceed to radical cystectomy (RC) without neoadjuvant chemotherapy. Perioperative enfortumab vedotin (EV) plus pembrolizumab with RC is an alternative option, but little is known about its cost-effectiveness compared with surgery alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of perioperative EV plus pembrolizumab for cisplatin-ineligible patients with localized MIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This economic evaluation developed a decision-analytic Markov model that compared neoadjuvant EV plus pembrolizumab followed by RC and adjuvant EV plus pembrolizumab (intervention arm) vs RC alone (control arm). The sample consisted of simulated patients with MIBC who were ineligible for or declined cisplatin-based neoadjuvant chemotherapy. The model was informed by efficacy and safety data from the KEYNOTE-905\/EV-303 trial, which had a median (range) follow-up of 25.6 (11.8-53.7) months. Analyses were performed between October 2025 and August 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-7\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>The 2 treatment strategies were (1) neoadjuvant EV plus pembrolizumab followed by RC and adjuvant EV plus pembrolizumab and (2) RC alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Outcomes included life-years, quality-adjusted life-years (QALYs), and direct medical costs estimated from a Medicare payer perspective over a 10-year horizon. Incremental cost-effectiveness ratio (ICER) was assessed against a willingness-to-pay threshold of $100\u202f000 per QALY. Scenario, 1-way, and probabilistic sensitivity analyses were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The model consisted of 10\u202f000 patients (age at baseline, 73 years; 77 900 males [77.9%]). Over 10 years, adding perioperative EV plus pembrolizumab to treatment was associated with increased projected survival from 4.12 to 5.63 life-years per patient, quality-adjusted survival from 3.20 to 4.51 QALYs per patient, and total costs from $317\u202f513 to $412\u202f160. Higher upfront perioperative therapy costs were partially offset by lower postprogression treatment costs ($12\u202f578 per patient for the intervention arm vs $238\u202f729 per patient for the control arm). Perioperative EV plus pembrolizumab with RC achieved an ICER of $72\u202f460 per QALY vs RC alone and therefore represented a cost-effective treatment approach. In 1-way and scenario sensitivity analyses, the cost-effectiveness result was sensitive to alternative assumptions for key factors, including time horizon length, adjuvant therapy utilization rates, patient age, postprogression treatment mix, drug costs, and health utility before disease progression. In the probabilistic sensitivity analysis, perioperative EV plus pembrolizumab with RC had a 53% probability of being cost-effective vs RC alone at the prespecified willingness-to-pay threshold of $100\u202f000 per QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi261095-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this economic evaluation of a simulated cohort of patients with cisplatin-ineligible MIBC, clinical trial\u2013informed modeling suggested that adopting the perioperative EV plus pembrolizumab intervention extends overall survival and quality-adjusted survival and is likely cost-effective in the US.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.40370","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:21Z","timestamp":1792510221000},"page":"e2640370","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Zhuo Tony","family":"Su","sequence":"first","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Garman","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Rivera Lopez","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Talwar","sequence":"additional","affiliation":[{"name":"Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Chelluri","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Burles A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiten D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Urology, Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine K.","family":"Smith","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmish","family":"Singla","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H.","family":"Hoffman-Censits","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil H.","family":"Patel","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[{"name":"Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[{"name":"Division of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max R.","family":"Kates","sequence":"additional","affiliation":[{"name":"The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"4","key":"zoi261095r1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines insights: bladder cancer, version 3.2024.","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"zoi261095r2","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines.","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"13","key":"zoi261095r3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma.","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi261095r4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi261095r5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi261095r6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274.","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi261095r7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma.","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi261095r8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer.","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi261095r9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer.","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi261095r10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","article-title":"Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action.","volume":"4","author":"Bhanvadia","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"zoi261095r11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer.","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"zoi261095r12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"zoi261095r13","first-page":"1","article-title":"United States life tables, 2023.","volume":"1","author":"Arias","year":"2025","journal-title":"Natl Vital Stat Rep"},{"issue":"9","key":"zoi261095r14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi261095r15","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer.","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"7867","key":"zoi261095r16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"5","key":"zoi261095r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13938","article-title":"International cost-effectiveness analysis of durvalumab in stage III non-small cell lung cancer.","volume":"7","author":"Kareff","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi261095r18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.6004\/jnccn.2025.7129","article-title":"Cost-effectiveness of perioperative durvalumab with neoadjuvant gemcitabine\/cisplatin in muscle-invasive bladder cancer treatment.","volume":"24","author":"Su","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi261095r19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/13696998.2024.2329019","article-title":"Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective.","volume":"27","author":"Brodtkorb","year":"2024","journal-title":"J Med Econ"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2855494\/su_2026_oi_261095_1791898658.09231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:21Z","timestamp":1792510221000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2855494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.40370","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}